|Dr. Marc Rubin M.D.||Exec. Chairman||368k||N/A||62|
|Mr. Sunil Bhonsle M.B.A.||Chief Exec. Officer, Pres, Sec. and Director||491k||N/A||67|
|Brian E. Crowley||VP of Fin.||N/A||N/A||N/A|
|Dr. Katherine L. Beebe Ph.D.||Chief Devel. Officer and Exec. VP||N/A||N/A||N/A|
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinsons disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.
Titan Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 5; Compensation: 7.